SMN1 and proximal spinal muscular atrophy: By promoting the inclusion of exon 7 in SMN2 transcripts, treatment with risdiplam increases production of full-length, functional SMN protein, thereby addressing the underlying cause of SMA pathophysiology-progressive motor neuron degeneration due to SMN protein deficiency.